INBRX-109

DRUG2 trials

Sponsors

Inhibrx Biosciences, Inc

Conditions

Colorectal AdenocarcinomaConventional ChondrosarcomaEwing Sarcoma

Phase 1

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

RecruitingNCT03715933

Inhibrx Biosciences, IncColorectal Adenocarcinoma, Ewing Sarcoma

Start: 2018-10-08End: 2029-06-01Target: 411Updated: 2026-09-08

Phase 2

Study of INBRX-109 in Conventional Chondrosarcoma

Active, not recruitingNCT04950075

Inhibrx Biosciences, IncConventional Chondrosarcoma

Start: 2021-09-23End: 2026-12-01Updated: 2026-07-14

Related Papers

The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.

Journal of Clinical Oncology2026-05-27

Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).

Journal of Clinical Oncology2026-05-27

EXTH-100. Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ

Neuro-Oncology2025-11-01

Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma

Clinical Cancer Research2025-03-189 citations

Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study.

Journal of Clinical Oncology2025-01-271 citations

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research2023-06-0240 citations

A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma.

Journal of Clinical Oncology2022-06-017 citations